Results 101 to 110 of about 5,711,116 (385)

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. [PDF]

, 2013
The current first-line treatment for advanced metastatic prostate cancer, i.e. docetaxel-based therapy, is only marginally effective. The aim of the present study was to determine whether such therapy can be improved by combining docetaxel with Aneustat (
Collins, Colin C, Gao, Allen C, Gout, Peter W, Liu, Chengfei, Qu, Sifeng, Wang, Kendric, Wang, Yuwei, Wang, Yuzhuo, Wu, Rebecca, Xue, Hui   +9 more
core   +1 more source

Cancer statistics, 2020

Ca, 2020
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population‐based cancer occurrence.
R. Siegel, K. D. Miller, A. Jemal
semanticscholar   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Impact of COVID-19 on the time to counseling and treatment of prostate cancer

The Aging Male
Purpose This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a “minimal ...
Dejan K. Filipas, Randi M. Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A. Ludwig, Hans Heinzer, Thomas Steuber   +10 more
doaj   +1 more source

What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review

BMJ Open, 2020
Objective To investigate the risk of prostate cancer-specific mortality (PCSM) following initial negative systematic transrectal ultrasound-guided (TRUS) prostate biopsies.Design Systematic review.Data sources PubMed and Embase were searched using a ...
Klaus Brasso, Martin Andreas Roder, Sandra Miriam Kawa, Signe Benzon Larsen, John Thomas Helgstrand, Peter Iversen   +5 more
doaj   +1 more source

MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. [PDF]

, 2019
Prostate cancer is the most commonly diagnosed cancer in men with African American men disproportionally suffering from the burden of this disease.
Aqeel, Rasha, Cagle, Patrice, Chimeh, Uchechukwu, Collins, Sean P, Dahiya, Rajvir, Kumar, Deepak, Niture, Suryakant, Ramalinga, Malathi, Rios-Colon, Leslimar, Srivastava, Anvesha, Suy, Simeng   +10 more
core   +1 more source

A core outcome set for localised prostate cancer effectiveness trials [PDF]

, 2017
Objective: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Background: Many treatments exist for localised prostate cancer, although it is unclear which offers the ...
Abel, Paul, Ahmed, Hashim U., Akehurst, Gary, Almquist, Robert, Beck, Karl, Bekema, Hanneke, Budd, David, Campbell, Marion, Canfield, Steven, Catto, James, Cornford, Philip, Cross, William, Dahm, Philipp, Ewen, Alexander, Grant, Judith, Heer, Rakesh, Hurst, David, Jones, Rob, Kockelbergh, Roger, Lam, Thomas, MacDonald, Graham, Mackie, Andrew, MacLennan, Sara, MacLennan, Steven, Mason, Malcolm, McClinton, Sam, McLaren, Duncan, McNeill, Alan, Mostafid, Hugh, Mottet, Nicolas, N'Dow, James, Pearce, Ian, Pennet, Linda, Ramsay, Craig, Royle, Justine, Schreuder, Hans, Stewart, Grant D., Vale, Luke, van der Poel, Henk, Wardlaw, Kevin, Wiegel, Thomas, Williamson, Paula R.   +41 more
core   +1 more source

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

New England Journal of Medicine, 2004
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone ...
D. Petrylak, C. Tangen, M. Hussain, P. Lara, Jeffrey A. Jones, M. Taplin, P. Burch, D. Berry, C. Moinpour, M. Kohli, M. Benson, E. Small, D. Raghavan, E. Crawford   +13 more
semanticscholar   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

BMC Cancer, 2019
Background The differences in progression-free survival (PFS) and cancer-specific survival (CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of metastasis, and Heng criteria risk are unclear. In this study, we compared
Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung   +7 more
doaj   +1 more source